Alembic Pharma gets USFDA nod for Parkinson’s treatment drug

New Delhi: Drug firm Alembic Pharmaceuticals Thursday said it has received approval from the US health regulator for Pramipexole Dihydrochloride extended-release tablets used for the treatment of Parkinson’s disease. The approval from the United States Food and Drug Administration (USFDA) is for the company’s abbreviated new drug application (ANDA) for Pramipexole Dihydrochloride extended-release tablets, in the strengths of 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, and 4.5 mg, Alembic Pharmaceuticals said in a filing to BSE.

The approved product is a therapeutic equivalent to the reference listed drug product (RLD) Mirapex ER tablets, of Boehringer lngelheim Pharmaceuticals Inc.

Quoting IQVIA data, Alembic Pharma said Pramipexole Dihydrochloride extended-release tablets have an estimated market size of USD 38.6 million for twelve months ending December 2017.

The company currently has a total of 84 ANDA approvals (71 final approvals and 13 tentative approvals) from USFDA, it added.

Shares of Alembic Pharmaceuticals were trading at Rs 587.05 apiece on BSE, up 1.04 per cent from its previous close.

  • Related Posts

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    Mankind Pharma shares jumped nearly 8% on Tuesday to an intraday high of Rs 2,500 on the NSE after the company reported a 38% year-on-year rise in Q2 profit after…

    GLP-1 injections recalled across the US over sterility concerns

    A nationwide recall of compounded tirzepatide injections in the United States has raised fresh concerns about the safety of weight-loss medicines. The recall, initiated by Apothecary Pharma LLC over concerns…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    GLP-1 injections recalled across the US over sterility concerns

    GLP-1 injections recalled across the US over sterility concerns

    Govt allows third-party agencies to conduct departmental inspections

    Govt allows third-party agencies to conduct departmental inspections

    Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

    Fridge-free vaccines could reach more people, but there are still practical challenges in African settings

    Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

    Low Bone Density in Nearly 7 in 10 Patients Pointing to High Risk of Osteoporosis

    Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher

    Hat Trick of PhDs in Health: Three Cheers for the Rare Researcher